A team led by researchers from the ETH Zürich and the University of Basel has used a combination of mass spectrometry data and machine learning to predict antibiotic resistance of clinical bacterial samples. The results, which were published in the Jan. 10, 2022, issue of Nature Medicine, could speed the identification of optimal antibiotic regimens for patients. Read More
Targeting VEGF and DLL4 at the same time in solid tumors is an approach that continues to entice researchers, with such firms as Abbvie Inc., Compass Therapeutics Inc. and Oncxerna Therapeutics Inc. working to come up with oncology solutions. Read More
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million. Read More
PERTH, Australia – Australia has recently established new research and discovery centers to study psychedelic treatments for mental health disorders. Headquartered Melbourne, the Psychae Institute is a global research collaboration supported by a AU$40 million (US$29 million) investment from a North American biotechnology company. Read More
Following Philip Morris International Inc.’s controversial takeover of respiratory drug firm Vectura plc, British American Tobacco plc (BAT) is also making inroads into medical research with U.K.-based Kbio Holdings Ltd., a biotech focused on plant-based medicine. Read More
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adagene, AI, Ascletis, First Wave, Gritstone, GSK, Imcyse, Oncopeptides, On Target, Redhill, Rhythm, Rubius, Spago, Tempus. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Imcyse.
